종양학 정보 시스템 시장 - 세계 시장 예측(2026-2032년)

The Oncology Information Systems Market is projected to grow by USD 5.70 billion at a CAGR of 6.67% by 2032.

Oncology Information Systems (OIS) are becoming foundational to modern cancer care by connecting radiation oncology, medical oncology, surgical oncology, pathology, imaging, pharmacy, survivorship, and administrative workflows into a coordinated digital environment. As the global cancer burden rises and treatment pathways become more complex, healthcare providers are prioritizing oncology software that improves clinical decision support, treatment planning, multidisciplinary collaboration, patient engagement, and regulatory documentation. Verified public health data show cancer remains one of the leading causes of death worldwide, increasing pressure on health systems to strengthen digital oncology infrastructure. The strongest demand drivers include the shift toward precision oncology, the expansion of radiotherapy and systemic therapy services, growing use of electronic health records, and the need to manage longitudinal cancer data across screening, diagnosis, treatment, follow-up, and outcomes monitoring. Interoperability remains central: oncology information systems must exchange data with hospital information systems, laboratory information systems, radiology information systems, picture archiving and communication systems, electronic prescribing tools, cancer registries, and billing platforms. Adoption is also shaped by data protection rules, reimbursement models, workforce availability, infrastructure readiness, and national cancer control priorities. In this environment, OIS platforms are moving beyond scheduling and recordkeeping to become integrated clinical operating systems for oncology service delivery.

Transformative Shifts in the Oncology Information Systems Landscape

The oncology information systems landscape is being reshaped by several structural shifts in cancer care delivery. First, oncology is moving from episodic treatment to continuous care management, requiring platforms that support longitudinal patient records, symptom tracking, survivorship plans, toxicity monitoring, and remote care coordination. Second, precision medicine is increasing the importance of integrating genomic, molecular pathology, imaging, and treatment response data into routine workflows. Third, multidisciplinary tumor boards are becoming more data-intensive, creating demand for systems that consolidate imaging, pathology, staging, treatment history, and guideline-based recommendations into a single clinical view. Fourth, cloud-based and hybrid deployment models are gaining attention as hospitals seek scalability, cybersecurity resilience, disaster recovery, and easier updates, while still complying with local health data regulations. Fifth, value-based care and quality reporting are encouraging oncology providers to document outcomes, adverse events, treatment adherence, and patient-reported measures more consistently. Finally, workforce pressures in oncology are accelerating automation in scheduling, dose documentation, referral management, prior authorization support, and clinical task routing. These shifts are transforming OIS from department-specific tools into enterprise-grade oncology data platforms.

Cumulative Impact of Artificial Intelligence on Oncology Information Systems

Artificial intelligence is having a cumulative impact on oncology information systems by improving the way cancer data is captured, interpreted, prioritized, and used in clinical workflows. AI-enabled tools can support image analysis, radiotherapy contouring assistance, treatment planning optimization, clinical trial matching, risk stratification, adverse event prediction, and automated extraction of structured data from clinical notes. Natural language processing is particularly relevant because oncology records contain large volumes of unstructured information across pathology reports, imaging narratives, physician notes, molecular test results, and discharge summaries. When integrated responsibly, AI can reduce documentation burden, help identify gaps in care, and support more timely decisions. However, implementation must be governed by clinical validation, transparency, bias monitoring, cybersecurity controls, and alignment with medical device and health software regulations. AI does not replace oncologists, physicists, dosimetrists, nurses, pharmacists, or data managers; rather, it strengthens oncology information systems by enabling faster data synthesis and more consistent workflow execution. The most practical near-term opportunity is embedding AI into existing oncology workflows where it can improve efficiency, standardization, and quality assurance without disrupting clinical accountability.

Key Regional Insights for Oncology Information Systems

Regional adoption of oncology information systems varies according to cancer burden, digital health maturity, infrastructure investment, regulatory frameworks, and specialist availability. In Asia-Pacific, rising cancer incidence, expanding radiotherapy capacity, national digital health programs, and increasing investment in tertiary cancer centers are driving the need for scalable oncology software, particularly in China, India, Japan, South Korea, Australia, and ASEAN health systems. North America remains one of the most digitally mature regions, supported by widespread electronic health record use, structured reimbursement processes, cancer registry infrastructure, and strong demand for interoperability, cybersecurity, and quality reporting across integrated delivery networks. Latin America is progressing through public and private investments in cancer diagnosis and treatment, with oncology information systems increasingly used to improve referral management, radiotherapy scheduling, and documentation in countries such as Brazil and Mexico, although disparities in access and infrastructure remain important constraints. Europe is shaped by universal healthcare models, national cancer plans, cross-border digital health initiatives, and strict data protection requirements, making interoperability, privacy-by-design architecture, and standardized reporting critical purchasing criteria. The Middle East is investing in specialized oncology centers, digital hospitals, and national health transformation programs, particularly in Gulf health systems where connected care and advanced radiotherapy infrastructure are expanding. Africa presents a highly diverse environment, where OIS adoption is concentrated in major urban and referral centers; the most urgent needs include affordable deployment models, cancer registry strengthening, workforce training, and systems that can operate reliably amid uneven connectivity and resource constraints.

Key Group Insights for Oncology Information Systems

Group-level dynamics highlight how policy alignment, economic capacity, and healthcare cooperation influence oncology information system adoption. ASEAN countries are advancing digital health at different speeds, with regional demand linked to hospital modernization, cancer screening expansion, and the need for interoperable systems that can support both public and private oncology services. The GCC is characterized by significant investment in smart hospitals, national health data platforms, and specialized cancer care, creating strong conditions for integrated oncology information systems that support multilingual workflows, centralized records, and advanced treatment coordination. The European Union emphasizes secure data exchange, health data governance, quality improvement, and cancer mission initiatives, encouraging OIS solutions that align with interoperability standards, privacy regulations, and cross-institution research readiness. BRICS countries represent a large and complex operating environment because of substantial cancer burden, growing oncology infrastructure, and expanding digital health policy activity; however, implementation models must adapt to wide differences in funding, connectivity, workforce capacity, and public-private care delivery. G7 countries generally demonstrate high levels of oncology specialization, regulatory oversight, clinical research activity, and digital maturity, making demand strongest for advanced analytics, AI governance, outcome reporting, and seamless integration with enterprise health IT. NATO member countries overlap significantly with high-income digital health markets, where cybersecurity, operational resilience, data sovereignty, and continuity of care are increasingly important criteria for oncology information systems used in mission-critical healthcare environments.

Key Country Insights for Oncology Information Systems

Country-level insights show that oncology information systems must be tailored to local healthcare structures and digital readiness. In the United States, adoption is influenced by extensive electronic health record use, complex reimbursement documentation, cancer center networks, clinical trial activity, and quality reporting requirements, making interoperability and workflow automation essential. Canada emphasizes provincial health governance, cancer agency coordination, and equitable access across large geographies, supporting demand for systems that enable standardized oncology documentation and remote collaboration. Mexico is advancing oncology digitization through public and private hospital modernization, with opportunities tied to referral coordination, radiotherapy workflow management, and structured cancer data capture. Brazil has a large cancer care network and increasing digital health activity, but regional disparities make scalable and cost-effective OIS deployment important. The United Kingdom benefits from national cancer strategies, integrated care pathways, and strong health data governance, creating demand for systems that support treatment waiting-time management, multidisciplinary care, and outcomes reporting. Germany's highly regulated healthcare environment and strong hospital infrastructure encourage adoption of secure, interoperable oncology platforms aligned with digital health modernization. France prioritizes national cancer planning, data protection, and coordinated specialty care, supporting OIS use in treatment documentation, tumor board workflows, and quality monitoring. Russia's oncology digitization is linked to federal health initiatives and regional cancer center development, with emphasis on service coordination across a large geography. Italy and Spain are advancing digital oncology through regional health systems, cancer networks, and hospital modernization, where interoperability and standardized clinical pathways are major priorities. China is expanding oncology capacity rapidly, supported by hospital digitalization, AI-enabled diagnostics interest, and high demand for systems that manage large patient volumes. India faces a rising cancer burden and uneven specialist access, making affordable, scalable, and cloud-ready oncology information systems valuable for tertiary centers and emerging cancer networks. Japan's aging population and advanced oncology infrastructure support demand for precision oncology integration, radiotherapy workflow optimization, and longitudinal care management. Australia emphasizes connected care across metropolitan and regional settings, with OIS platforms supporting multidisciplinary treatment, survivorship, and telehealth-enabled coordination. South Korea's strong digital hospital ecosystem and advanced oncology capabilities create demand for integrated platforms that support AI readiness, structured data use, and high-efficiency treatment workflows.

Actionable Recommendations for Oncology Information Systems Leaders

Industry leaders should prioritize interoperability, clinical usability, cybersecurity, and measurable workflow improvement when developing or adopting oncology information systems. Solutions should support open standards, structured oncology terminology, bidirectional integration with enterprise health IT, and reliable exchange of imaging, pathology, genomics, pharmacy, and treatment planning data. Vendors and providers should co-design workflows with oncologists, radiation therapists, physicists, nurses, pharmacists, tumor registrars, and administrators to reduce documentation burden and improve adoption. AI features should be introduced with transparent validation, human oversight, audit trails, and bias monitoring. Healthcare organizations should also strengthen data governance, role-based access, disaster recovery, and compliance with local privacy regulations. For emerging markets and resource-constrained settings, modular deployment, cloud or hybrid options, training support, and low-bandwidth functionality can improve implementation success. Leaders should evaluate OIS performance through clinical and operational indicators such as treatment coordination efficiency, documentation completeness, scheduling accuracy, care pathway adherence, adverse event tracking, registry reporting quality, and patient engagement outcomes.

Research Methodology for Oncology Information Systems Analysis

This executive summary is built on a structured secondary research approach using verified public-domain and industry-relevant sources, including health authority publications, cancer control policy documents, digital health regulations, oncology practice guidelines, peer-reviewed literature, hospital technology adoption trends, and recognized global health datasets. The analysis evaluates oncology information systems through clinical, operational, regulatory, technological, and regional lenses while excluding market estimation, market sizing, market share, and market forecasting. Insights are synthesized to identify demand drivers, implementation barriers, AI-related implications, interoperability needs, regional adoption patterns, and country-specific healthcare factors. The research process emphasizes source credibility, cross-validation of themes across multiple evidence categories, and relevance to oncology care delivery. Particular attention is given to cancer care pathways, radiotherapy and systemic therapy workflows, data governance, electronic health record integration, privacy requirements, and digital transformation initiatives. The methodology is designed to provide decision-ready intelligence for healthcare providers, technology developers, policymakers, investors, and strategic planners without relying on speculative projections.

Conclusion

Oncology information systems are becoming essential infrastructure for coordinated, data-driven cancer care. Their role is expanding from administrative management to integrated clinical decision support, treatment coordination, outcome documentation, AI-enabled workflow assistance, and enterprise oncology data governance. Adoption is strongest where cancer care systems are investing in digital health, interoperability, precision medicine, and quality reporting, but implementation priorities differ across regions, groups, and countries. The future of OIS will be shaped by secure data exchange, responsible AI, cloud scalability, user-centered design, and the ability to connect complex oncology workflows across care settings. Organizations that align oncology software strategy with clinical needs, regulatory expectations, and measurable operational outcomes will be better positioned to improve care continuity, strengthen multidisciplinary collaboration, and support high-quality cancer treatment in increasingly complex healthcare environments.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Oncology Information Systems Market, by Offering

• 7.1. Introduction
• 7.2. Software
  • 7.2.1. Oncology EMR Systems
  • 7.2.2. Treatment Planning Systems
  • 7.2.3. Patient Information Management Systems
  • 7.2.4. Clinical Decision Support Systems
  • 7.2.5. Oncology Image Management Systems
  • 7.2.6. Practice Management Systems
  • 7.2.7. Clinical Workflow Management Systems
  • 7.2.8. Data Management & Analytics Systems
• 7.3. Services
  • 7.3.1. Consulting & Training
  • 7.3.2. Installation & Integration
  • 7.3.3. Maintenance & Support

8. Oncology Information Systems Market, by Functionality

• 8.1. Introduction
• 8.2. Patient Scheduling & Registration
• 8.3. Treatment Planning & Simulation
• 8.4. Patient Information & Care Management
• 8.5. Dose Management & Verification
• 8.6. Image Storage & Management
• 8.7. Clinical Decision Support

9. Oncology Information Systems Market, by Deployment Mode

• 9.1. Introduction
• 9.2. Cloud-Based
• 9.3. On-Premise
• 9.4. Hybrid

10. Oncology Information Systems Market, by Application

• 10.1. Introduction
• 10.2. Medical Oncology
• 10.3. Radiation Oncology
• 10.4. Surgical Oncology

11. Oncology Information Systems Market, by End User

• 11.1. Introduction
• 11.2. Hospitals
• 11.3. Specialty Cancer Centers
• 11.4. Ambulatory Care Centers
• 11.5. Academic & Research Medical Institutions

12. Oncology Information Systems Market, by Region

• 12.1. Asia-Pacific
• 12.2. Europe
• 12.3. North America
• 12.4. Latin America
• 12.5. Africa
• 12.6. Middle East

13. Oncology Information Systems Market, by Group

• 13.1. NATO
• 13.2. G7
• 13.3. BRICS
• 13.4. European Union
• 13.5. ASEAN
• 13.6. GCC

14. Oncology Information Systems Market, by Country

• 14.1. China
• 14.2. United States
• 14.3. Japan
• 14.4. India
• 14.5. Germany
• 14.6. United Kingdom
• 14.7. Australia
• 14.8. France
• 14.9. South Korea
• 14.10. Italy
• 14.11. Canada
• 14.12. Russia
• 14.13. Brazil
• 14.14. Mexico
• 14.15. Spain

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Accuray Incorporated
• 16.2. Advanced Data Systems Corporation
• 16.3. Altai Oncology
• 16.4. Brainlab AG
• 16.5. Carevive Systems
• 16.6. Cota Healthcare Inc.
• 16.7. CureMD Healthcare
• 16.8. DOSIsoft SA
• 16.9. Elekta AB
• 16.10. EndoSoft LLC
• 16.11. Epic Systems Corporation
• 16.12. F. Hoffmann-La Roche AG
• 16.13. GE HealthCare Technologies Inc.
• 16.14. Inspirata Inc.
• 16.15. International Business Machines Corporation
• 16.16. Koninklijke Philips N.V.
• 16.17. McKesson Corporation
• 16.18. Medisolv Inc.
• 16.19. Mevion Medical Systems Inc.
• 16.20. MICA Information Systems
• 16.21. Optum Inc.
• 16.22. Oracle Corporation
• 16.23. PAIGE.AI Inc.
• 16.24. Prowess Inc.
• 16.25. RaySearch Laboratories AB (publ)
• 16.26. Siemens Healthineers AG
• 16.27. Syapse Inc.
• 16.28. Tempus Labs Inc.